Century Therapeutics, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for IPSC, updated each market day.
IPSC AI Sentiment
AI predicts Century Therapeutics, Inc. Common Stock stock is likely to decrease over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Century Therapeutics, Inc. Common Stock
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
Sector
Exchange
Market Cap
$406,173,414
Cap Tier
Employees
78
Headquarters
PHILADELPHIA, PA
Listed Since
June 18, 2021
Website
IPSC Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
IPSC Volatility
Century Therapeutics, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
